APO Research
Talk to an analyst

APO RESEARCH · REPORT

Short Bowel Syndrome (SBS) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Short Bowel Syndrome (SBS) Drugs Market Outlook and Growth Opportunities 2026

20 December 2025196 pages

Choose your research edition.

Industry ResearchShort Bowel Syndrome (SBS) Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Short Bowel Syndrome (SBS) Drugs Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Short Bowel Syndrome (SBS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Short Bowel Syndrome (SBS) Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Short Bowel Syndrome (SBS) Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Short Bowel Syndrome (SBS) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Short Bowel Syndrome (SBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Short Bowel Syndrome (SBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Short Bowel Syndrome (SBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Short Bowel Syndrome (SBS) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Short Bowel Syndrome (SBS) Drugs market include Takeda, Merck, Zealand Pharma, Sancilio Pharmaceuticals, OxThera, Nutrinia, Naia Pharmaceuticals, Emmaus Medical and Ardelyx, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Short Bowel Syndrome (SBS) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Short Bowel Syndrome (SBS) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Short Bowel Syndrome (SBS) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Short Bowel Syndrome (SBS) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Short Bowel Syndrome (SBS) Drugs Segment by Company

Takeda

Merck

Zealand Pharma

Sancilio Pharmaceuticals

OxThera

Nutrinia

Naia Pharmaceuticals

Emmaus Medical

Ardelyx

Short Bowel Syndrome (SBS) Drugs Segment by Type

Glutamine

Growth Hormone

Glucagon-Like Peptide-2 (GLP-2)

Other

Short Bowel Syndrome (SBS) Drugs Segment by Application

Hospitals

Clinics

Retail Pharmacies

Short Bowel Syndrome (SBS) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Short Bowel Syndrome (SBS) Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Short Bowel Syndrome (SBS) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Short Bowel Syndrome (SBS) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Short Bowel Syndrome (SBS) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Short Bowel Syndrome (SBS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Short Bowel Syndrome (SBS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Short Bowel Syndrome (SBS) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Short Bowel Syndrome (SBS) Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Short Bowel Syndrome (SBS) Drugs industry.

Chapter 3: Detailed analysis of Short Bowel Syndrome (SBS) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Short Bowel Syndrome (SBS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Short Bowel Syndrome (SBS) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Short Bowel Syndrome (SBS) Drugs Industry Trends Table 2. Short Bowel Syndrome (SBS) Drugs Industry Drivers Table 3. Short Bowel Syndrome (SBS) Drugs Industry Opportunities and Challenges Table 4. Short Bowel Syndrome (SBS) Drugs Industry Restraints Table 5. Global Short Bowel Syndrome (SBS) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Short Bowel Syndrome (SBS) Drugs Revenue Share by Company (2021-2026) Table 7. Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Short Bowel Syndrome (SBS) Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Short Bowel Syndrome (SBS) Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Short Bowel Syndrome (SBS) Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Short Bowel Syndrome (SBS) Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Short Bowel Syndrome (SBS) Drugs Company, Product Type & Application Table 13. Global Short Bowel Syndrome (SBS) Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Short Bowel Syndrome (SBS) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Glutamine Table 18. Significant Companies of Growth Hormone Table 19. Significant Companies of Glucagon-Like Peptide-2 (GLP-2) Table 20. Significant Companies of Other Table 21. Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Short Bowel Syndrome (SBS) Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Short Bowel Syndrome (SBS) Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type (2021-2026) Table 30. Global Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospitals Table 32. Significant Companies of Clinics Table 33. Significant Companies of Retail Pharmacies Table 34. Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Short Bowel Syndrome (SBS) Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Short Bowel Syndrome (SBS) Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application (2021-2026) Table 43. Global Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application (2027-2032) Table 44. Global Short Bowel Syndrome (SBS) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Short Bowel Syndrome (SBS) Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Region (2021-2026) Table 47. Global Short Bowel Syndrome (SBS) Drugs Sales by Region (2027-2032) & (K Units) Table 48. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Region (2027-2032) Table 49. Global Short Bowel Syndrome (SBS) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Short Bowel Syndrome (SBS) Drugs Sales Value Share by Region (2021-2026) Table 52. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Short Bowel Syndrome (SBS) Drugs Sales Value Share by Region (2027-2032) Table 54. Global Short Bowel Syndrome (SBS) Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Short Bowel Syndrome (SBS) Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Short Bowel Syndrome (SBS) Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2026) & (K Units) Table 59. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Country (2021-2026) Table 60. Global Short Bowel Syndrome (SBS) Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Country (2027-2032) Table 62. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Short Bowel Syndrome (SBS) Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Short Bowel Syndrome (SBS) Drugs Sales Value Market Share by Country (2027-2032) Table 66. Takeda Company Information Table 67. Takeda Business Overview Table 68. Takeda Short Bowel Syndrome (SBS) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Takeda Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 70. Takeda Recent Development Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck Short Bowel Syndrome (SBS) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Merck Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 75. Merck Recent Development Table 76. Zealand Pharma Company Information Table 77. Zealand Pharma Business Overview Table 78. Zealand Pharma Short Bowel Syndrome (SBS) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Zealand Pharma Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 80. Zealand Pharma Recent Development Table 81. Sancilio Pharmaceuticals Company Information Table 82. Sancilio Pharmaceuticals Business Overview Table 83. Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 85. Sancilio Pharmaceuticals Recent Development Table 86. OxThera Company Information Table 87. OxThera Business Overview Table 88. OxThera Short Bowel Syndrome (SBS) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. OxThera Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 90. OxThera Recent Development Table 91. Nutrinia Company Information Table 92. Nutrinia Business Overview Table 93. Nutrinia Short Bowel Syndrome (SBS) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Nutrinia Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 95. Nutrinia Recent Development Table 96. Naia Pharmaceuticals Company Information Table 97. Naia Pharmaceuticals Business Overview Table 98. Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 100. Naia Pharmaceuticals Recent Development Table 101. Emmaus Medical Company Information Table 102. Emmaus Medical Business Overview Table 103. Emmaus Medical Short Bowel Syndrome (SBS) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Emmaus Medical Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 105. Emmaus Medical Recent Development Table 106. Ardelyx Company Information Table 107. Ardelyx Business Overview Table 108. Ardelyx Short Bowel Syndrome (SBS) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Ardelyx Short Bowel Syndrome (SBS) Drugs Product Portfolio Table 110. Ardelyx Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Short Bowel Syndrome (SBS) Drugs Distributors List Table 114. Short Bowel Syndrome (SBS) Drugs Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Short Bowel Syndrome (SBS) Drugs Product Image Figure 2. Global Short Bowel Syndrome (SBS) Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Short Bowel Syndrome (SBS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Short Bowel Syndrome (SBS) Drugs Sales (2021-2032) & (K Units) Figure 5. Global Short Bowel Syndrome (SBS) Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Short Bowel Syndrome (SBS) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Glutamine Image Figure 10. Growth Hormone Image Figure 11. Glucagon-Like Peptide-2 (GLP-2) Image Figure 12. Other Image Figure 13. Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Short Bowel Syndrome (SBS) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Short Bowel Syndrome (SBS) Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Short Bowel Syndrome (SBS) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type (2021-2032) Figure 19. Hospitals Image Figure 20. Clinics Image Figure 21. Retail Pharmacies Image Figure 22. Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Short Bowel Syndrome (SBS) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Short Bowel Syndrome (SBS) Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Short Bowel Syndrome (SBS) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Short Bowel Syndrome (SBS) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Short Bowel Syndrome (SBS) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Short Bowel Syndrome (SBS) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Short Bowel Syndrome (SBS) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Short Bowel Syndrome (SBS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Short Bowel Syndrome (SBS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Short Bowel Syndrome (SBS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Short Bowel Syndrome (SBS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Short Bowel Syndrome (SBS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Short Bowel Syndrome (SBS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Short Bowel Syndrome (SBS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Short Bowel Syndrome (SBS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Short Bowel Syndrome (SBS) Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Short Bowel Syndrome (SBS) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Short Bowel Syndrome (SBS) Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Short Bowel Syndrome (SBS) Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Glutamine
  • Growth Hormone
  • Glucagon-Like Peptide-2 (GLP-2)
  • Other
Applications
  • Hospitals
  • Clinics
  • Retail Pharmacies
Companies covered
  • Takeda
  • Merck
  • Zealand Pharma
  • Sancilio Pharmaceuticals
  • OxThera
  • Nutrinia
  • Naia Pharmaceuticals
  • Emmaus Medical
  • Ardelyx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Short Bowel Syndrome (SBS) Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Short Bowel Syndrome (SBS) Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Short Bowel Syndrome (SBS) Drugs Market Dynamics
  1. 2.1 Short Bowel Syndrome (SBS) Drugs Industry Trends
  2. 2.2 Short Bowel Syndrome (SBS) Drugs Industry Drivers
  3. 2.3 Short Bowel Syndrome (SBS) Drugs Industry Opportunities and Challenges
  4. 2.4 Short Bowel Syndrome (SBS) Drugs Industry Restraints
3 Short Bowel Syndrome (SBS) Drugs Market by Company
  1. 3.1 Global Short Bowel Syndrome (SBS) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Short Bowel Syndrome (SBS) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Short Bowel Syndrome (SBS) Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Short Bowel Syndrome (SBS) Drugs Company Ranking (2024-2026)
  6. 3.6 Global Short Bowel Syndrome (SBS) Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Short Bowel Syndrome (SBS) Drugs Company Product Type and Application
  8. 3.8 Global Short Bowel Syndrome (SBS) Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Short Bowel Syndrome (SBS) Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Short Bowel Syndrome (SBS) Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Short Bowel Syndrome (SBS) Drugs Market by Type
  1. 4.1 Short Bowel Syndrome (SBS) Drugs Type Introduction
  2. 4.1.1 Glutamine
  3. 4.1.2 Growth Hormone
  4. 4.1.3 Glucagon-Like Peptide-2 (GLP-2)
  5. 4.1.4 Other
  6. 4.2 Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Type
  7. 4.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Short Bowel Syndrome (SBS) Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Type
  11. 4.3.1 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type (2021-2032)
5 Short Bowel Syndrome (SBS) Drugs Market by Application
  1. 5.1 Short Bowel Syndrome (SBS) Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Application
  6. 5.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Short Bowel Syndrome (SBS) Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Short Bowel Syndrome (SBS) Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Application
  10. 5.3.1 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application (2021-2032)
6 Short Bowel Syndrome (SBS) Drugs Regional Sales and Value Analysis
  1. 6.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Region (2027-2032)
  5. 6.3 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Short Bowel Syndrome (SBS) Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Short Bowel Syndrome (SBS) Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Short Bowel Syndrome (SBS) Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Short Bowel Syndrome (SBS) Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Short Bowel Syndrome (SBS) Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Short Bowel Syndrome (SBS) Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Short Bowel Syndrome (SBS) Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Short Bowel Syndrome (SBS) Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Short Bowel Syndrome (SBS) Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Short Bowel Syndrome (SBS) Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Short Bowel Syndrome (SBS) Drugs Sales Value Share by Country, 2025 VS 2032
7 Short Bowel Syndrome (SBS) Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Country (2027-2032)
  6. 7.4 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Short Bowel Syndrome (SBS) Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Short Bowel Syndrome (SBS) Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Short Bowel Syndrome (SBS) Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Short Bowel Syndrome (SBS) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Short Bowel Syndrome (SBS) Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Short Bowel Syndrome (SBS) Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Short Bowel Syndrome (SBS) Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Short Bowel Syndrome (SBS) Drugs Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Zealand Pharma
  14. 8.3.1 Zealand Pharma Company Information
  15. 8.3.2 Zealand Pharma Business Overview
  16. 8.3.3 Zealand Pharma Short Bowel Syndrome (SBS) Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Zealand Pharma Short Bowel Syndrome (SBS) Drugs Product Portfolio
  18. 8.3.5 Zealand Pharma Recent Developments
  19. 8.4 Sancilio Pharmaceuticals
  20. 8.4.1 Sancilio Pharmaceuticals Company Information
  21. 8.4.2 Sancilio Pharmaceuticals Business Overview
  22. 8.4.3 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Portfolio
  24. 8.4.5 Sancilio Pharmaceuticals Recent Developments
  25. 8.5 OxThera
  26. 8.5.1 OxThera Company Information
  27. 8.5.2 OxThera Business Overview
  28. 8.5.3 OxThera Short Bowel Syndrome (SBS) Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 OxThera Short Bowel Syndrome (SBS) Drugs Product Portfolio
  30. 8.5.5 OxThera Recent Developments
  31. 8.6 Nutrinia
  32. 8.6.1 Nutrinia Company Information
  33. 8.6.2 Nutrinia Business Overview
  34. 8.6.3 Nutrinia Short Bowel Syndrome (SBS) Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Nutrinia Short Bowel Syndrome (SBS) Drugs Product Portfolio
  36. 8.6.5 Nutrinia Recent Developments
  37. 8.7 Naia Pharmaceuticals
  38. 8.7.1 Naia Pharmaceuticals Company Information
  39. 8.7.2 Naia Pharmaceuticals Business Overview
  40. 8.7.3 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Portfolio
  42. 8.7.5 Naia Pharmaceuticals Recent Developments
  43. 8.8 Emmaus Medical
  44. 8.8.1 Emmaus Medical Company Information
  45. 8.8.2 Emmaus Medical Business Overview
  46. 8.8.3 Emmaus Medical Short Bowel Syndrome (SBS) Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Emmaus Medical Short Bowel Syndrome (SBS) Drugs Product Portfolio
  48. 8.8.5 Emmaus Medical Recent Developments
  49. 8.9 Ardelyx
  50. 8.9.1 Ardelyx Company Information
  51. 8.9.2 Ardelyx Business Overview
  52. 8.9.3 Ardelyx Short Bowel Syndrome (SBS) Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ardelyx Short Bowel Syndrome (SBS) Drugs Product Portfolio
  54. 8.9.5 Ardelyx Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Short Bowel Syndrome (SBS) Drugs Value Chain Analysis
  2. 9.1.1 Short Bowel Syndrome (SBS) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Short Bowel Syndrome (SBS) Drugs Sales Mode & Process
  6. 9.2 Short Bowel Syndrome (SBS) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Short Bowel Syndrome (SBS) Drugs Distributors
  9. 9.2.3 Short Bowel Syndrome (SBS) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst